| Literature DB >> 35043564 |
Dharaniya Sakthivel1,2,3, Beatriz E Bolívar2,3, Lisa Bouchier-Hayes2,3,4.
Abstract
zVAD-fmk is a widely used pan-caspase inhibitor that blocks apoptosis but has undesirable side effects, including autophagy. In this issue, Needs et al. propose that zVAD-fmk induces autophagy by inhibiting the N-glycanase NGLY1 rather than caspases. NGLY1 is essential for the ERAD response and patients with inactivating mutations in NGLY1 present with neurodevelopmental defects and organ dysfunction. The ability of NGLY1 to inhibit basal levels of autophagy may contribute to this pathology. This study demonstrates possible crosstalk between protein turnover and autophagy while also underscoring the importance of specificity when using chemical tools to interrogate these pathways. Comment on https://doi.org/10.1111/febs.16345.Entities:
Keywords: NLGY1; apoptosis; autophagy; caspase; zVAD-fmk
Mesh:
Substances:
Year: 2022 PMID: 35043564 PMCID: PMC9177521 DOI: 10.1111/febs.16346
Source DB: PubMed Journal: FEBS J ISSN: 1742-464X Impact factor: 5.622